SPONSOR: ALTO NEUROSCIENCE INC-

INDICATION: MAJOR DEPRESSIVE DISORDER

STUDY: ALTO-300-201: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ALTO-300 WITH AN OPEN-LABEL EXTENSION IN ADULTS WITH MAJOR DEPRESSIVE DISORDER

LOCATION: GEORGIA

SPONSOR: JANSSEN RESEARCH & DEVELOPMENT

INDICATION: MAJOR DEPRESSIVE DISORDER

STUDY: JNJ-42847922: A TWO-PART MULTICENTER, DOUBLE-BLIND, RANDOMIZED PLACEBO-CONTROLLED STUDY TO EVALUATE EFFICACY AND SAFETY AND THE MAINTENANCE OF EFFECT OF 20-MG SELTOREXANT AS ADJUNCTIVE THERAPY TO ANTIDEPRESSANTS IN ADULT AND ELDERLY PATIENTS WITH MAJOR DEPRESSIVE DISORDER WITH INSOMNIA SYMPTOMS

LOCATION: GEORGIA

SPONSOR:  MERCK SHARP & DOHME LLC

INDICATION: COVID-19

STUDY: 023: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MOLNUPIRAVIR (MK-4482) IN NON-HOSPITALIZED ADULTS WITH COVID-19 AT HIGH RISK FOR DISEASE PROGRESSION FOR WHOM TREATMENT WITH NIRMATRELVIR/RITONAVIR IS NOT CLINICALLY APPROPRIATE OR ACCESSIBLE

LOCATION: GEORGIA

SPONSOR:  Otsuka Pharmaceutical Development & Commercialization, Inc.

INDICATION: MAJOR DEPRESSIVE DISORDER

STUDY: A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Flexible Doses of SEP-363856 as Adjunctive Therapy in the Treatment of Adults with Major Depressive Disorder

LOCATION: GEORGIA